Primary Spinal Cord Astrocytomas: Two-Center Clinical Experience of Low- and High-Grade Lesions

Primary spinal cord astrocytomas are rare, fatal, and poorly studied. This study included a 2-center, retrospective analysis of primary spinal cord astrocytoma patients from 1997 to 2020. Patients with drop metastases or without at least one follow-up were excluded. Seven World Health Organization g...

Full description

Saved in:
Bibliographic Details
Published in:World neurosurgery 2022-11, Vol.167, p.e1006-e1016
Main Authors: Snyder, M. Harrison, Yu-Der Wang, Andy, Ampie, Leonel, Sarathy, Danyas, Chatrath, Ajay, Asthagiri, Ashok R., Shaffrey, Christopher I., Smith, Justin S., Shaffrey, Mark E., Yen, Chun-Po, Buchholz, Avery L., Syed, Hasan R., Kryzanski, James, Wu, Julian K., Heilman, Carl B.
Format: Article
Language:English
Subjects:
Astrocytoma - diagnostic imaging
Astrocytoma - therapy
Central nervous system neoplasms
Combined Modality Therapy
Glioma
Humans
Postoperative complications
Retrospective Studies
Spinal cord neoplasms
Spinal Cord Neoplasms - diagnostic imaging
Spinal Cord Neoplasms - pathology
Spinal Cord Neoplasms - surgery
Temozolomide
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary spinal cord astrocytomas are rare, fatal, and poorly studied. This study included a 2-center, retrospective analysis of primary spinal cord astrocytoma patients from 1997 to 2020. Patients with drop metastases or without at least one follow-up were excluded. Seven World Health Organization grade I, 6 grade II, 7 grade III, and 4 grade IV astrocytoma patients were included. Older patients had higher grades (median 20 years in grade I vs. 36.5 in grade IV). The median follow-up was 15 months. Thirteen patients were discharged to rehabilitation. Eight patients demonstrated radiographic progression. Adjuvant therapy was utilized more in higher grades (5 of 13 grades III vs. all 11 grades IIIIV). Six patients died (1 death in grades III vs. 5 in grades IIIIV). Ten patients had worsened symptoms at the last follow-up. The median progression-free survival in grade I, II, III, and IV tumors was 116, 36, 8, and 8.5 months, respectively. The median overall survival in grade I, II, III, and IV tumors was 142, 69, 19, and 12 months, respectively. Thrombotic complications occurred in 2 patients, one with isocitrate dehydrogenasewild type glioblastoma. Outcomes worsen with higher grades and lead to difficult postoperative periods. Clinicians should be vigilant for thromboembolic complications. Further research is needed to understand these rare tumors.
ISSN:1878-8750
1878-8769
1878-8769
DOI:10.1016/j.wneu.2022.08.130